Knockdown of lncRNA NORAD inhibits the proliferation, inflammation and fibrosis of human mesangial cells under high-glucose conditions by regulating the miR-485/NRF1 axis

LINNA WANG1*, XIAOYING YUAN1*, LIFENG LIAN, HUALI GUO3, HONGXIA ZHANG1 and MINGHUI ZHANG1

1Department of Nephrology, 2Laboratory Department and 3Blood Purification Center, Shengli Oilfield Central Hospital, Dongying, Shandong 257000, P.R. China

Received April 10, 2020; Accepted February 11, 2021

DOI: 10.3892/etm.2021.10306

Correspondence to: Dr Minghui Zhang, Department of Nephrology, Shengli Oilfield Central Hospital, 31 Jinan Road, Dongying, Shandong 257000, P.R. China
E-mail: zhangminghui244@163.com

*Contributed equally

Key words: diabetic nephropathy, non-coding RNA activated by DNA damage, microRNA-485, nuclear respiratory factor 1, high-glucose
miRNAs act as efficient inhibitors in DN progression (20). For example, miR-544 attenuates diabetic renal injury by suppressing glomerulosclerosis and inflammation (21). miR-320a may be a potential curative target in DN (22). miR-874 overexpression alleviated renal injury in DN rats (23). Notably, miR-485 may serve as a regulator of inflammatory and fibrotic responses (24). In a recent study, miR-485 suppressed MC infiltration and proliferation in an in vitro model of DN (25).

Additionally, lncRNAs may act as competing endogenous RNAs or sponges of miRNAs. NORAD has been reported to regulate numerous miRNAs in several types of human disease, including miR-136-5p in retinoblastoma (26), miR-144-3p in hepatocellular carcinoma (27), miR-520a-3p in non-small cell lung cancer (28) and miR-214 in gastric cancer (16). However, the regulatory mechanisms between IncRNA NORAD and miR-485 have not yet been reported.

The present study investigated the effects of IncRNA NORAD on human (H)MC proliferation, inflammation and fibrosis and investigated the regulatory mechanisms between NORAD and miR-485/nuclear regulatory factor 1 (NRF1). The present study revealed that the NORAD/miR-485/NRF1 axis will be a theoretical basis for DN-targeted therapy.

Materials and methods

Tissue collection. A total of 21 patients with DN without other complications were selected in Shengli Oilfield Central Hospital (Dongying, China) between March 2017 and June 2018. The patients included 11 males and 10 females (age range, 46-64 years; mean age, 54.6±6.2 years). These patients had not received treatment within 3 months before admission. Pathological kidney and adjacent normal tissues were obtained by biopsy. Each patient provided written informed consent and agreed to the study being published. The present study was approved by the Ethics Committee of Shengli Oilfield Central Hospital (approval no. Q/ZXY-Y-ZY-WB-LL202037).

Cell grouping and transfection. HMCs were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. DMEM containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) was used to culture the cells at 37°C in 5% CO₂. Small interfering (siRNA)-negative control (si-NC; 5'-UUCUCCGAACGUUCACGUG-3') and siRNA-NORAD-1/2 (si-NORAD-1, 5'-AACGCCACCUUUG UGAACAGUA-3'; si-NORAD-2, 5'-GAGAUAUGGAAUGACA-3') were obtained from Sangon Biotech Co., Ltd. NORAD overexpression (ov-NORAD), NRF1 overexpression (ov-NRF1), miR-485 mimics (5'-AGAGGCUGGCUGUGAUAUU-3'), miR-485 inhibitors (5'-UCUCCGAACGU UGACGUTT-3'), miR-485 inhibitor NC (5'-CAGCUACAGGGCUCCUCUCU-3'), and inhibitor NC (5'-CAUGUAUUUGAUAACAAA-3') were procured from Guangzhou RiboBio Co., Ltd. HMCs were transfected with the aforementioned agents (all 50 nM) using a Lipofectamine RNAiMAX kit (Invitrogen; Thermo Fisher Scientific, Inc.) for 48 h at 37°C. In addition, the HMCs (6x10⁴ cells/well) were further divided into high glucose (HG; 30 mM) and normal glucose (NG; 5.5 mM) groups. At 48 h after treatment, the cells were harvested to perform the following experiments.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from HMCs using a TRIzol® reagent kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. In accordance with the manufacturer's protocols of GoScript™ reverse transcription system (Promega Corporation), the extracted RNA was initially reverse transcribed into cDNA at 37°C for 60 min, followed by 85°C for 5 min and then subjected to qPCR analyses with the Applied Biosystems SYBR™ Green PCR Master mix (Thermo Fisher Scientific, Inc.). The thermocycling conditions were: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 10 sec, 60°C for 20 sec and 72°C for 34 sec. U6 or GAPDH was used as the internal reference standard. The primers were designed as follows: NORAD forward: 5'-GGAGGAGTGCCTTGAACCT-3' and reverse, 5'-CAAACACCAAAATGAAAT-3'; miR-485 forward, 5'-CCAGGCTCTACCATCATTCGAGAAGC-3' and reverse, 5'-CGGATCCCTTAGGTCAACGCTTGTG-3'; NRF1 forward, 5'-TTTACTCTGCTGATGTTGTG-3' and reverse, 5'-CCTCTGATGCTTGTGTT-3'; U6 forward, 5'-GCTTCCGGCAGCATATACTAATA-3' and reverse, 5'-CGCTTGACGGAATGGGTATTCGCGGTCT-3' and GAPDH forward, 5'-GAAGGTGAAGGGTGGTGTC-3' and reverse, 5'-GAAGATGTTGTGATTGGATTTCT-3'. Gene expression was quantified using the 2−ΔΔCT method (29).

Western blot analysis. Radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology) containing protease inhibitors was used to extract proteins from cells. The protein concentrations were determined using a bicinchoninic acid Protein assay kit (Thermo Fisher Scientific, Inc.). A total of 50 µg of protein/lane was separated via 10% SDS-PAGE (Boster Biological Technology). The resolved proteins were then transferred onto polyvinylidene fluoride membranes. Blocking was performed using 5% bovine serum albumin (Thermo Fisher Scientific, Inc.) at room temperature for 2 h. Following blocking, the membranes were incubated overnight at 4°C with primary antibodies against NRF1 (1:1,000; cat. no. ab175932; Abcam) and GAPDH (1:1,000; cat. no. ab8245; Abcam). Next, the membranes were washed three times in TBS-Tween-20 (0.05%). The secondary antibody horseradish peroxidase-conjugated anti-mouse immunoglobulin G (1:2,000; cat. no. ab6728; Abcam) was added and incubated for 1 h at room temperature. GADPH was used as the internal reference. The membranes were developed using an ECL reagent (Thermo Fisher Scientific, Inc.) under Gel-Pro analyzer (version 4.0; Media Cybernetics, Inc.).

Cell viability assay. MTT assays were used to determine HMC viability. Cells were seeded onto a 96-well plate with 2x10⁴ cells/well and cultured in serum-free medium overnight at 37°C. Subsequently, cells were incubated under the designated glucose conditions for 24, 48, 72 and 96 h at 37°C. Next, 20 µl MTT (Merck KGaA) was added to each well and the cells were incubated for another 2 h at 37°C. The supernatant was removed and the formazan crystals were dissolved using DMSO (150 µl/well). The absorbance at 450 nm was analysed using a Multiskan Spectrum microplate reader (Thermo Fisher Scientific, Inc.).
ELISA. According to manufacturer protocols, the levels of inflammatory [tumour necrosis factor (TNF)-α (cat. no. 70-EK182HS-96), interleukin (IL)-1β (cat.no.70-EKI01BHS-96)andIL-6(cat.no.70-EK106/2-96)and fibrotic [type IV collagen (Col. IV) (cat. no. RK-009-001-106), fibronectin (FN; cat. no. RK-KOA0169) and plasminogen activator inhibitor 1 (PAI-1) (cat. no. 70-EK1136-96)] factors in HMCs were measured using specific ELISA kits purchased from Multisciences Biotech, Ltd. The absorbance at 450 nm was determined using a Multiskan Spectrum microplate reader (Thermo Fisher Scientific, Inc.).

Target prediction. The miRNA targets of NORAD were predicted using StarBase software version 2.0 (http://starbase.sysu.edu.cn/), and 272 targets were predicted. Among these miRNA targets, miR-485 was selected for the following assays due to its important role in DN (25) and unknown regulatory association with NORAD. In addition, the mRNA targets of miR-485 were predicted using mirDB software version 3.0 (http://mirdb.org/), and 1,646 targets were predicted. NRF1 was selected for the following assays due to its important role in renal diseases (30,31).

Dual-luciferase reporter assay. To verify the direct interactions between miR-485 and NORAD/NRF1, a dual-luciferase reporter assay was performed. Briefly, the mutant type (MUT) and wild type (WT) of NORAD/NRF1 binding sequences were cloned into the pGL3-promoter (Promega Corporation) to generate the recombinant vectors pGL3-NORAD-WT/MUT or pGL3-NRF1-WT/MUT. Cells were co-transfected with the aforementioned recombinant vectors and miR-485 mimic/miR-NC (all 50 nM) using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 48 h. The supernatant was used to measure relative luciferase activity on a Dual-Luciferase Reporter assay system (Promega Corporation). The activity of firefly luciferase was normalized to that of Renilla luciferase.

Statistical analysis. SPSS version 20.0 (IBM Corp.) and GraphPad Prism version 5.01 (GraphPad Software, Inc.) were used to perform the statistical analyses. Data are expressed as the mean ± standard deviation. Student’s t-tests were used to assess the differences between groups (paired, Figs. 1A, 3D and 5C; unpaired, Figs. 1B, 3E and 5D). One-way analysis of variance (ANOVA) was used to investigate the differences among multiple groups. Following ANOVA, pairwise comparisons were performed using Tukey’s multiple comparisons tests. P<0.05 was considered to indicate a statistically significant difference. All experiments were conducted in triplicate in at least three independent experiments.

Results

NORAD is highly expressed in DN tissues and HG-stimulated HMCs. The NORAD expression in DN and normal tissues was detected by RT-qPCR. The results demonstrated higher expression in DN tissues compared with normal tissues (P<0.001; Fig. 1A). Meanwhile, NORAD expression was significantly increased in HG-stimulated HMCs compared with the NG group (P<0.05; Fig. 1B).

Knockdown of NORAD inhibits HG-induced HMC proliferation, inflammation and fibrosis. To investigate the possible role of NORAD in DN pathogenesis in vitro, si-NORAD-1/-2 was initially transfected into HMCs to detect the silencing efficiency. As illustrated in Fig. 2A, RT-qPCR demonstrated significantly decreased NORAD expression following transfection of si-NORAD-1 and si-NORAD-2 (P<0.01). Following treatment with HG, NORAD expression was also significantly decreased in the HG + si-NORAD-1 and HG + si-NORAD-2 groups (P<0.01; Fig. 2B). si-NORAD-1 was selected in the following experiments due to its greater silencing efficiency. The results of the MTT assay demonstrated increased HMC viability in the HG + si-NC group compared with those in the NG group, whilst cell activity was partially inhibited in the HG + si-NORAD group compared with the NG group (P<0.05; Fig. 2C). Similarly, the ELISA results demonstrated highly increased levels of inflammatory factors (IL-6, IL-1β and TNF-α) in the HG + si-NC group compared with those in the NG group, which was attenuated in the HG + si-NORAD group (P<0.01; Fig. 2D-F). The levels of PAI-1, Col. IV and FN were higher in the HG + si-NC group compared with the NG group, which was partially reversed in the HG + si-NORAD group (P<0.01; Fig. 2G-I).

NORAD targets miR-485. Analysis using StarBase software demonstrated potential binding sequences between IncRNA
NORAD and miR-485 (Fig. 3A). The luciferase activity in the NORAD WT/miR-485 mimics group was decreased compared with that in the NORAD WT/miR-NC group (P<0.01; Fig. 3B). miR-485 expression was significantly downregulated in the HG + si-NC group compared with in the NG group, which was attenuated in the HG + si-NORAD group (P<0.01; Fig. 3C). RT-qPCR assays demonstrated decreased miR-485 expression in DN tissues compared with in normal tissues (P<0.001; Fig. 3D). The expression of miR-485 was also decreased in the HG group compared with in the NG group (P<0.01; Fig. 3E). These data indicated a negative regulatory association between NORAD and miR-485.

**NORAD reverses the inhibitory effects of miR-485 on HG-induced HMCs.** Next, miR-485 mimics, miR-485 inhibitor and miR-485 mimics + ov-NORAD were transfected into HMCs to detect the transfection efficiency. The expression of miR-485 was upregulated in the miR-485 mimics group compared with in the miR-NC group, whilst the inverse was observed in the miR-485 inhibitor group compared with the inhibitor NC group (P<0.01; Fig. 4A). Meanwhile, compared with the miR-485 mimics + ov-NC group, miR-485 expression in the miR-485 mimics + ov-NORAD group was partially inhibited (P<0.01; Fig. 4A). NORAD expression was then determined following transfection. The results of RT-qPCR analysis demonstrated
that the expression of NORAD was upregulated by ov-NORAD, but was partially suppressed by ov-NORAD + miR-485 mimics (P<0.01; Fig. 4B). In addition, it was also discovered that miR-485 expression was significantly decreased in the HG group; its expression was upregulated in the HG + miR-485 mimics group and downregulated in the HG + miR-485 inhibitor group (P<0.01; Fig. 4C). All the results suggested that miR-485 expression was significantly decreased in the HG group; its expression was upregulated in the HG + miR-485 mimics group and downregulated in the HG + miR-485 inhibitor group (P<0.01; Fig. 4C).

Identification of NRF1 as the target gene of miR-485. Using miRDB software, the potential binding sites between NRF1 and miR-485 were predicted (Fig. 5A). Dual-luciferase reporter assays demonstrated significantly decreased luciferase activity in the NRF1 WT/miR-485 mimics group compared with in the control group (P<0.01; Fig. 5B). These results indicated that NRF1 was a direct target gene of miR-485 (P<0.01; Fig. 5B). The RT-qPCR results suggested that the expression of NRF1 was higher in DN tissues compared with in normal tissues (P<0.001; Fig. 5C). Similar to the mRNA levels, the results of the western blot analysis demonstrated downregulation of the NRF1 protein level in the HG + miR-485 mimics group compared with that in the HG + miR-NC group (P<0.01; Fig. 5D). These results suggested that miR-485 inhibited NRF1 expression.

Therefore, the results suggested that NORAD may affect the occurrence and development of DN in vitro by regulating miR-485 expression.

**Figure 3. miR-485 is a direct target of NORAD. (A) Predicted complementary binding site of NORAD and miR-485. (B) Luciferase activity in HMCs co-transfected with pGL3-NORAD WT/pGL3-NORAD MUT and miR-485 mimics/NC as determined by a dual luciferase reporter assay. **P<0.01 vs. miR-NC. (C) Expression of miR-485 in HMCs detected by RT-qPCR. **P<0.01 vs. NG; ***P<0.01 vs. HG + si-NC. (D) Expression of miR-485 in DN tissues (n=21) and adjacent normal tissues (n=21) detected by RT-qPCR. ***P<0.001 vs. normal. (E) Expression of miR-485 in HG-induced HMCs and NG HMCs detected by RT-qPCR. **P<0.01 vs. NG; miR, microRNA; NORAD, non-coding RNA activated by DNA damage; HMCs, human mesangial cells; si, small interfering RNA; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; HG, high glucose; NG, normal glucose; DN, diabetic nephropathy; WT, wild-type; MUT, mutant.
Figure 4. NORAD reverses the inhibitory effects of miR-485 on HG-induced HMCs. (A) Expression of miR-485 following transfection of miR-485 mimics/inhibitor or miR-485 mimics + ov-NORAD detected by RT-qPCR. **P<0.01 vs. miR-NC; ***P<0.01 vs. miR-485 mimics + ov-NC; &^P<0.01 vs. inhibitor NC. (B) Expression of NORAD following transfection of ov-NORAD or ov-NORAD + miR-485 mimics detected by RT-qPCR. **P<0.01 vs. ov-NC; ***P<0.01 vs. ov-NORAD + miR-NC. (C) Expression of miR-485 in HG-induced HMCs detected by RT-qPCR. **P<0.01 vs. NG; ***P<0.01 vs. HG + miR-NC; &^P<0.01 vs. HG + inhibitor NC. (D) Viability of HG-induced HMCs measured by an MTT assay. **P<0.01 vs. miR-NC; ^#P<0.05 vs. miR-485 mimics. (E) Levels of IL-6, IL-1β and TNF-α in HG-induced HMCs measured via ELISA. **P<0.01 vs. miR-NC; ^#P<0.05 vs. miR-485 mimics. (F) Contents of Col. IV, FN and PAI-1 in HG-induced HMCs measured via ELISA. **P<0.01 vs. miR-NC; ^#P<0.05 vs. miR-485 mimics. miR, microRNA; NORAD, non-coding RNA activated by DNA damage; NG, normal glucose; HG, high glucose; HMCs, human mesangial cells; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; ov, overexpression vector; NC, negative control; OD, optical density; TNF, tumour necrosis factor; IL, interleukin; Col. IV, type IV collagen; FN, fibronectin; PAI-1, plasminogen activator inhibitor 1.

Figure 5. NRF1 is a target gene of miR-485. (A) Predicted complementary binding site of NRF1 and miR-485. (B) Luciferase activity in HMCs co-transfected with pGL3-NRF1 WT/pGL3-NRF1 MUT and miR-485 mimics/NC determined by a dual luciferase reporter assay. **P<0.01 vs. mimics NC. (C) Expression of NRF1 in DN tissues (n=21) and adjacent normal tissues (n=21). ***P<0.001 vs. normal. (D) Protein expression of NRF1 in HMCs detected via western blot analysis. **P<0.01 vs. HG + miR-NC. NRF1, nuclear respiratory factor 1; miR, microRNA; HMCs, human mesangial cells; NC, negative control; DN, diabetic nephropathy; WT, wild-type; MUT, mutant; HG, high glucose.
NORAD knockdown inhibits proliferation, inflammation and fibrosis in HG-induced HMCs by regulating the miR-485/NRF1 axis. The expression of NORAD and miR-485 following co-transfection was detected. The results of RT-qPCR demonstrated that NORAD expression was significantly increased in the si-NORAD + miR-485 inhibitor and si-NORAD + ov-NRF1 groups compared with their controls (si-NORAD + miR-NC and si-NORAD + ov-NC, respectively; P<0.05; Fig. 6A). Furthermore, the expression of miR-485 was inhibited by co-transfection with si-NORAD + miR-485 inhibitor compared with si-NORAD + inhibitor NC (P<0.01; Fig. 6B). The transfection efficiency of ov-NRF1 was subsequently determined using RT-qPCR, which demonstrated that NRF1 expression was increased by ov-NRF1 (P<0.01; Fig. 6C). The aforementioned results indicated that si-NORAD + miR-485 inhibitor or ov-NRF1 was successfully transfected into HMCs. Western blot analysis demonstrated downregulated NRF1 protein expression following transfection of si-NORAD, while co-transfection with si-NORAD + miR-485 inhibitor and si-NORAD + ov-NRF1 resulted in significant upregulation of NRF1 (P<0.01 vs. si-NC; P<0.05 vs. si-NORAD + inhibitor NC; Fig. 6D). The viability of HG-induced HMCs measured by MTT assays also showed significant differences (P<0.01 vs. si-NC; P<0.05 vs. si-NORAD + inhibitor NC; Fig. 6E). The levels of IL-6, IL-1β and TNF-α in HG-induced HMCs as determined via ELISA were significantly higher in the si-NORAD + miR-485 inhibitor and si-NORAD + ov-NRF1 groups compared with their controls (P<0.01 vs. si-NC; P<0.05 vs. si-NORAD + inhibitor NC; Fig. 6F). The contents of Col. IV, FN and PAI-1 in HG-induced HMCs as determined via ELISA were also significantly increased in the si-NORAD + miR-485 inhibitor and si-NORAD + ov-NRF1 groups compared with their controls (P<0.01 vs. si-NC; P<0.05 vs. si-NORAD + inhibitor NC; Fig. 6G).
miR-485 inhibitor or ov-NRF1 reversed this inhibitory effect (P<0.05; Fig. 6D). MTT assays demonstrated significantly inhibited HG-induced HMC viability in the si-NORAD group compared with that in the si-NC group. Meanwhile, cell viability was partially promoted in the si-NORAD + miR-485 inhibitor and si-NORAD + ov-NRF1 groups compared with in the si-NORAD group (P<0.05; Fig. 6E). Similarly, the ELISA results indicated that NORAD knockdown downregulated the levels of inflammatory (IL-6, IL-1β and TNF-α) and fibrotic (PAI-1, Col. IV and FN) factors. However, downregulation of miR-485 and upregulation of NRF1 reversed the effects of NORAD knockdown on inflammation and fibrosis in HG-induced HMCs (P<0.05; Fig. 6F and G). These results indicated that knockdown of NORAD may suppress HG-induced HMC proliferation, inflammation and fibrosis by regulating miR-485/NRF1.

Discussion

Increasing evidence has indicated that hyperglycaemia serves a major role in DN (32). Inflammatory and fibrotic reactions in diabetic patients are mainly caused by hyperglycaemia and ultimately accelerate the development of DN (33,34). Recent studies have demonstrated that lncRNAs serve a critical role in DN (25-27). A previous study reported upregulation of lncRNA antisense non-coding mitochondrial RNA-2 in DN tissues and HG-treated MCs (35). Another study observed significantly upregulated expression of lncRNA distal-less homeobox 6, opposite strand 1 (Dlx6os1) in MCs under HG conditions compared with NG conditions (36). Similarly, the present study identified that lncRNA NORAD was highly expressed in HG-stimulated HMCs and DN tissues. Therefore, NORAD may be a pathogenic factor and may serve as a biomarker for the prognosis of DN.

In the last decade, lncRNAs have been identified as important regulators of cell proliferation, inflammation and fibrosis in DN (13,27,28). Hyperglycaemia is widely proposed to affect different types of nephrocytes (32). Furthermore, MC proliferation, inflammation and fibrosis are the three major features of DN (13,27,28). Ma et al (37) reported that downregulation of lncRNA NEAT1 inhibited the proliferation, fibrosis and inflammation of mouse MCs in DN. Feng et al (7) observed that lncRNA brown fat lncRNA 1 interference attenuated renal inflammation fibrosis in DN. Furthermore, another study demonstrated that inhibition of lncRNA Dlx6os1 decreased cell proliferation and fibrosis in DN (36). In the present study, NORAD knockdown suppressed HG-stimulated HMC proliferation, inflammation and fibrosis. Similar to the results of the present study, a recent study also demonstrated that knockdown of NORAD decreased cell viability in mouse glomerular mesangial cells in DN (17). However, the previous study only investigated the mechanism of NORAD on cell proliferation. The results of the present study further revealed the involvement of lncRNA NORAD in regulating HMC proliferation, inflammation and fibrosis in DN.

Recent studies have reported that miRNAs act as regulatory factors in various cellular processes. For example, miRNAs affect cell proliferation, apoptosis, stress resistance and angiogenesis (38). Yao et al (23) reported that miR-874 alleviates renal injury and inflammatory response in DN. Jiang et al (20) observed that miR-342-3p-overexpression suppressed renal interstitial fibrosis in DN. The present study revealed decreased miR-485 expression in HG-stimulated HMCs and DN tissues. Furthermore, miR-485 was the direct target of lncRNA NORAD and inhibited HG-stimulated HMC proliferation, inflammation and fibrosis. Similar to the results of the present study, Wu et al (25) also demonstrated that miR-485 overexpression suppressed HG-induced HMC proliferation. The results demonstrated that miR-485 may inhibit DN progression. The present study also demonstrated that NORAD overexpression attenuated the inhibitory effects of miR-485 on HG-induced HMC proliferation, inflammation and fibrosis. These results suggested that NORAD may affect DN progression by regulating miR-485 expression.

Emerging evidence has suggested that NRF1 is an important regulatory factor in apoptosis (39). Zhang et al (39) reported that NRF1 overexpression inhibited the apoptosis of palmitate-stimulated human cardiac myocytes. Zhang et al (40) also indicated that NRF1 acts as a key regulator of chondrocyte apoptosis in osteoarthritis. The present study demonstrated significantly increased NRF1 expression in DN tissues and showed that transfection of miR-485 mimics into HG-stimulated HMCs inhibited NRF1 expression. Therefore, NRF1 was determined to be the target gene of miR-485. Furthermore, it was demonstrated that NRF1 expression was negatively regulated by miR-485, and that downregulation of miR-485 and upregulation of NRF1 reversed the effects of NORAD-knockdown on HG-induced HMC proliferation, inflammation and fibrosis. The results indicated that NORAD knockdown inhibited HG-induced HMC proliferation, inflammation and fibrosis by regulating miR-485 and NRF1 expression.

In conclusion, the results of the present study revealed that NORAD knockdown inhibited the proliferation, inflammation and fibrosis of HG-induced HMCs by regulating the in vitro expression of miR-485 and NRF1. However, the difference between in vitro and in vivo conditions is a limitation of the present study. Further studies are warranted to elucidate these issues. Despite this limitation, these findings suggest the potential of a novel strategy for treating DN.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LW and HG were responsible for the conception and design of the study, and project supervision and management. XY and HZ performed data acquisition and analysis. LL and MZ were involved in data analysis and visualization. All
authors confirmed the authenticity of all the raw data, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from each patient. The present study was approved by the Ethics Committee of Shengli Oilfield Central Hospital (approval no. Q/ZXYY-ZY-YWB-LL.202037).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


